Overactive Bladder (OAB)MCI Registration NumberFirst NameLast NameEmailPhone/MobileCityStateSpecialityBank DetailsUpload Cancelled Cheque (Max Size 2MB)Choose File Upload Pancard Details (Max Size 2MB)Choose File Questionnaire on: Overactive Bladder (OAB): A Perspective on Special Populations, Pharmacotherapy, and the Significance of Patient Awareness A] OAB Management for Special Populations (women, seniors, patients with comorbidities)1. In your clinical experience, which age group of women most frequently presents with OAB symptoms? Women between 18-40 years Women between 40-55 years Women between 50-65 years Women above 65 years2. In your experience, which is the most common precipitating factor for OAB in pre-menopausal women? Pregnancy and associated increase in pressure on bladder and pelvic floor Hormonal changes during pregnancy Vaginal childbirth or complications during the same Any others (please specify)Any others (please specify)3. In your experience, which is the most common precipitating factor for OAB in post-menopausal women? Hormonal changes at perimenopausal or menopausal stage History of vaginal childbirth or complications during the same Pelvic organ prolapse Diabetes Obesity or High BMI Hypertension Any others (Please specify)Any others (please specify)4. What is your preferred first-line treatment strategy for female OAB patients? Start treatment with behavioural therapies alone Start with pharmacotherapy alone Start treatment with combination of behavioural and pharmacotherapy for faster relief from symptoms Start treatment with behavioural therapies but add pharmacotherapy quickly if patient compliance is not good5. Which of the following comorbid conditions do you see most frequently in elderly patients with OAB? Diabetes Hypertension Stroke Neurological conditions (e.g. Parkinson’s disease) Age-related dementia Genitourinary conditions (e.g. vaginal atrophy in women or BPH in men) Any other (please specify)Any others (please specify)6. Based on your experience, how concerning are drug-drug interactions in elderly OAB patients who are on multiple medications for comorbid conditions? Not concerning Somewhat concerning Concerning Highly concerning7. How significant is the risk of cognitive impairment due to increased cholinergic burden when using antimuscarinics in elderly OAB patients? Not significant Somewhat significant Significant Highly significant8. How significant is the increased risk of falls in elderly OAB patients if they rush to the toilet due to urgency or frequency? Not significant Somewhat significant Significant Highly significantB] Pharmacotherapy Preferences for OAB Treatment9. Which is your preferred monotherapy option for treating OAB symptoms? Mirabegron Solifenacin Tolterodine Fesoterodine Any other? (please specify)Any others (please specify)10. In which clinical scenarios do you most commonly prescribe the combination of mirabegron and solifenacin? In patients with persistent OAB symptoms despite monotherapy In patients requiring greater symptom control from the start In patients who experience dose-limiting side effects with antimuscarinics alone Any other? (Please specify)Any others (please specify)11. Based on your clinical experience, how influential has the lower incidence of adverse effects with mirabegron been in your prescribing decisions? Not influential Moderately influential Influential Highly influential12. In your experience, how effective has mirabegron been in providing better control over urgency, frequency, and urinary leakage compared to other options? Not effective Moderately effective Effective Highly effective13. How significantly have your patients reported an improvement in their quality of life after being prescribed mirabegron? No improvement Mild improvement Moderate improvement Significant improvement14. What percentage of your OAB patients require mirabegron treatment for more than 6 months to maintain symptom control? Less than 25% 25-50% 50-75% 75-100% I do not usually prescribe mirabegron for more than 6 months15. How do you rate the overall safety profile of mirabegron for OAB compared to antimuscarinics? Mirabegron is significantly safer than antimuscarinics Slightly safer than antimuscarinics Comparable to antimuscarinics Less safe than antimuscarinics16. Based on your experience, how challenging is patient adherence to pharmacological therapies in OAB management? Not challenging Somewhat challenging Challenging Highly challenging17. How significant are concerns about drug-drug interactions when managing OAB in patients with comorbidities? Not significant Somewhat significant Significant Highly significantC] Patient Awareness Resources18. Do you ask your OAB patients to maintain a bladder diary or voiding intervals chart? Yes No Only for few patients who would be able to follow the instructions and comply19. Which of the following patient education tools would be useful for patients if kept in your clinic's waiting room? Symptom checklist using paper-pencil Symptom checker web page accessed via a QR code sticker in the waiting room None of these would be feasible for patients in my clinic20. How useful would it be to play a short informative video about OAB in your clinic's waiting room on a TV/digital screen? Yes, very useful for patient awareness Yes, useful Not very useful No, that would not be feasible in my clinic21. Which of the following patient education initiatives will help increase treatment adherence and improve quality of life? Take-home pamphlet illustrating Kegel exercises Bladder training mobile app with exercises, symptom tracker, fluid intake / voiding / medication reminders Bladder diary prints All of the above I have read and agree to the Terms and Conditions .Submit Form